GSK Receives Positive CHMP Opinion Recommending Approval of Jemperli (Dostarlimab) Plus Chemotherapy as a New Frontline Treatment for DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
October 17, 2023
October 17, 2023
LONDON, England, Oct. 17 (TNSres) -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on Oct. 16, 2023:
GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Jemperli (dostarlimab) in combination with carboplatin-paclitaxel (chemotherapy), for the treatment of adult patients with mismatch repair deficient (dMMR)/mic . . .
GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Jemperli (dostarlimab) in combination with carboplatin-paclitaxel (chemotherapy), for the treatment of adult patients with mismatch repair deficient (dMMR)/mic . . .